---
title: "RBC Capital maintains Cigna Group at Outperform, raises price target to $346 from $337"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/306141571.md"
description: "RBC Capital maintains Cigna Group at Outperform and raises its price target to $346 from $337. This adjustment implies a 21.2% upside from the November 18 close of $285.37. The update is part of recent analyst activity, with other firms like Wells Fargo, Jefferies, Piper Sandler, Bernstein, and Barclays maintaining various ratings and price targets ranging from $304 to $390 over the past month."
datetime: "2026-11-19T15:07:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/306141571.md)
  - [en](https://longbridge.com/en/news/306141571.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/306141571.md)
generator: "portal-rs"
---

# RBC Capital maintains Cigna Group at Outperform, raises price target to $346 from $337

RBC Capital maintained Cigna Group at Outperform and raised its price target to $346 from $337, a 2.7% increase.

The price target implies an upside of 21.2% from the Nov 18 close of $285.37.

**Recent analyst actions on Cigna Group**

| Date   | Firm          | Action    | Rating       | Price target |
| ------ | ------------- | --------- | ------------ | ------------ |
| Nov 13 | Wells Fargo   | Maintains | Equal-Weight | $325         |
| Nov 12 | Jefferies     | Maintains | Hold         | $304         |
| Nov 12 | Piper Sandler | Maintains | Overweight   | $360         |
| Nov 11 | Bernstein     | Maintains | Outperform   | $390         |
| Nov 9  | Barclays      | Maintains | Equal-Weight | $320         |

Across the five most recent analyst notes published on Cigna Group over the past 30 days, price targets range from $304 to $390.

Explore more price target data and ratings for Cigna Group on the , and track all previous and future analyst recommendations in the dedicated News Flow.

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [CI.US](https://longbridge.com/en/quote/CI.US.md)
- [AB.US](https://longbridge.com/en/quote/AB.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [JEF.US](https://longbridge.com/en/quote/JEF.US.md)
- [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)

## Related News & Research

- [Is Cigna Group (CI) Below Fair Value On Mixed Q3 2026 Earnings?](https://longbridge.com/en/news/305596810.md)
- [Bernstein Reaffirms Their Buy Rating on Cigna (CI)](https://longbridge.com/en/news/306105931.md)
- [Cigna beats Q3 adjusted revenue on segment growth, raises FY outlook](https://longbridge.com/en/news/304439506.md)
- [Elizabeth Warren Targets CVS, UnitedHealth and Cigna, Says Healthcare Giants ‘Take a Cut at Every Step’ as She Calls for Breaking Up Conglomerates](https://longbridge.com/en/news/305798081.md)
- [Sociedad Química y Minera de Chile S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now](https://longbridge.com/en/news/306368009.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**